The upcoming earnings report for Gilead Sciences, Inc. (GILD) is scheduled for Wednesday, May 6th. Analysts expect a consensus EPS of 1.89.
GILD's current price stands at $129.71, with a price increase of $1.96 (1.53%) from the previous close. Trading volume is at $1 million, representing a 16.03% increase compared to the average.
GILD's latest quarterly earnings were reported on Wednesday, April 22nd, with a consensus EPS of 1.86. The company continues to demonstrate strong financial performance.
GILD's forward dividend yield is at 2.53%, with a dividend per share of 82 cents MRQ and $3.19 TTM. This indicates the company's commitment to rewarding shareholders.
The company generated a free cash flow of $3.12 billion, with a net change in cash of $234 million. GILD maintains a healthy cash position, ending the period with $7.56 billion.
GILD reported a net income of $2.18 billion, with an EPS of $1.76. The company's profitability is reflected in its strong financial results.
Key financial ratios for GILD include a net profit margin of 27.55%, return on equity of 9.65%, and a price-to-earnings ratio of 17.46. These ratios indicate the company's financial stability and performance.
GILD's balance sheet highlights total assets of $59 billion and total liabilities of $36.41 billion. The company maintains a strong financial position.
This real-time financial report showcases Gilead Sciences, Inc.'s robust performance and positive outlook, making it an asset to watch in the market.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.